Gen-Probe (Nasdaq:GPRO) shareholders enjoyed a nice pop in late April when this diagnostics company announced that it was considering a sale. Those easy gains proved short-lived, though, as the stock gave up a lot of that jump when rumors started spreading in early June that the sale process had not been going well and there was only one interested party still in the bidding. (To help you determine if a stock is popping or if the entire market is moving, read Gauging The Strength Of A Market Move.)
TUTORIAL: Investing 101

Missing the quick and low-risk payday of a buyout would certainly be disappointing to some investors, but shareholders should not be too worried about this turn of events. While it would be discouraging to consider the idea that other companies do not see a lot of must-have value in Gen-Probe's business, there are other interpretations available. All in all, it may prove to be the case that life sciences companies look back on this opportunity with regret and shareholders ultimately benefit from the ongoing independence of Gen-Probe.

Last Man Standing?
When Gen-Probe initially put itself on the block, there was the collection of usual suspects in the mix as possible bidders. Gen-Probe's partner in the blood-screening business Novartis (NYSE:NVS) was on almost everyone's list, as were names like Abbott Labs (NYSE:ABT), General Electric (NYSE:GE), and a host of life sciences players like Thermo Fisher (NYSE:TMO) and Life Technologies (Nasdaq:LIFE).

If recent rumors are to be believed, though, that list has winnowed itself down quickly. Thermo Fisher likely took itself out of any consideration with the acquisition of Dionex, and other potential buyers like Danaher (NYSE:DHR) may be on the sidelines for similar reasons (while a company like Becton Dickinson (NYSE:BDX) would have antitrust problems). All in all, if the reports are to be believed, Novartis is the only company that is in the ring with a serious bid. (To learn more on how companies are bought and sold, check out Mergers And Acquisitions: Understanding Takeovers.)

Would a Deal Make Sense?
For Novartis, there would be some solid logic to a deal for Gen-Probe. The blood-screening business that the two companies share is not high-growth, but it's profitable and reliable. Moreover, diagnostics is an area where Novartis is notably lacking. Gen-Probe would bring immediate credibility in areas like HPV testing, molecular diagnostics (MDx), and STD testing, to say nothing of the future potential of additional MDx tests and personalized medicine (developing diagnostic tests to identify patients most likely to benefit from certain medications).

Of course, there is always a "but" in these conversations, and the "but" in this case is the valuation. Novartis would have to pay a pretty rich valuation for Gen-Probe and that may test the patience of shareholders a bit too far, as Novartis arguably still needs to demonstrate that it can deliver the promised results from past deals. (To help you determine to see if the Gen-Probe is a good deal, read Equity Valuation In Good Times And Bad.)

Going It Alone Not So Bad
It is not too hard to imagine that a hang-up in the Gen-Probe sale process revolves around the above-average uncertainty in the business. Gen-Probe is in many respects a company in transition, and companies may be unwilling to pay a large premium ahead of significant events like the U.S. launch of the new Panther platform and new assays in markets like prostate cancer and HPV. By the same token, maybe buyers want more assurance that Gen-Probe has a durable competitive advantage against the likes of Hologic (Nasdaq:HOLX) and Becton.

The good news for investors, though, is that Gen-Probe has made good deals in the past and has a solid growth outlook for the next three to five years. If new product launches go to plan, the stock should do at least as well as the market and if management can deliver some upside, the stock will do even better. Better still, buyers that are nervous today may be willing to come back later and pay a higher price for a little extra certainty.

The Bottom Line
Shareholders should certainly feel some disappointment that a sale seems less likely (or at least a bidding war), but it is probably better in the long run for the company to go its own way than to sell too cheaply just to get a deal done. What's more, the world of med-tech M&A is a strange one and unexpected bidders have a way of showing up (perhaps Johnson & Johnson (NYSE:JNJ) decides it just has to revitalize its diagnostics business, for instance). All in all, while Gen-Probe is not a terrifically cheap stock today, it's a solid company worth holding as an emerging player in growth markets like molecular diagnostics. (To learn more about the world of merger and acquisitions, check out Mergers And Acquisitions: Understanding Takeovers.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Stock Analysis

    Net Neutrality: Pros and Cons

    The fight over net neutrality has become an amazing spectacle. But at its core, it's yet another skirmish in cable television's war to remain relevant.
  2. Personal Finance

    Protect Your Home From Medicaid Liens

    Plan ahead for long-term care needs to protect your home and your estate.
  3. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  4. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  5. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  6. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  7. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  8. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  9. Professionals

    What to do During a Market Correction

    The market has what? Here's what you should consider rather than panicking.
  10. Mutual Funds & ETFs

    ETF Analysis: Vanguard Mid-Cap Value

    Take an in-depth look at the Vanguard Mid-Cap Value ETF, one of the largest and most popular mid-cap funds in the U.S. equity space.
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Hard-To-Sell Asset

    An asset that is extremely difficult to dispose of either due ...
  3. Sucker Yield

    When an investor has essentially risked all of his capital for ...
  4. PT (Perseroan Terbatas)

    An acronym for Perseroan Terbatas, which is Limited Liability ...
  5. Ltd. (Limited)

    An abbreviation of "limited," Ltd. is a suffix that ...
  6. BHD (Berhad)

    The suffix Bhd. is an abbreviation of a Malay word "berhad," ...
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!